BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27923595)

  • 1. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.
    Shan NL; Wahler J; Lee HJ; Bak MJ; Gupta SD; Maehr H; Suh N
    J Steroid Biochem Mol Biol; 2017 Oct; 173():122-129. PubMed ID: 27923595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer.
    Wahler J; So JY; Cheng LC; Maehr H; Uskokovic M; Suh N
    J Steroid Biochem Mol Biol; 2015 Apr; 148():148-55. PubMed ID: 25445919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
    So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
    J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma
    Shan NL; Minden A; Furmanski P; Bak MJ; Cai L; Wernyj R; Sargsyan D; Cheng D; Wu R; Kuo HD; Li SN; Fang M; Maehr H; Kong AN; Suh N
    Cancer Prev Res (Phila); 2020 Aug; 13(8):673-686. PubMed ID: 32467291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
    Wahler J; So JY; Kim YC; Liu F; Maehr H; Uskokovic M; Suh N
    Cancer Prev Res (Phila); 2014 Jun; 7(6):617-26. PubMed ID: 24691501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer.
    So JY; Lee HJ; Smolarek AK; Paul S; Wang CX; Maehr H; Uskokovic M; Zheng X; Conney AH; Cai L; Liu F; Suh N
    Mol Pharmacol; 2011 Mar; 79(3):360-7. PubMed ID: 21115634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer.
    So JY; Smolarek AK; Salerno DM; Maehr H; Uskokovic M; Liu F; Suh N
    PLoS One; 2013; 8(1):e54020. PubMed ID: 23326564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.
    So JY; Lin JJ; Wahler J; Liby KT; Sporn MB; Suh N
    PLoS One; 2014; 9(9):e107616. PubMed ID: 25229616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)
    Narvaez CJ; Bak MJ; Salman N; Welsh J
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106307. PubMed ID: 37030416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis and biological activities of BXL0124, a gemini analog of vitamin D.
    Belorusova AY; Suh N; Lee HJ; So JY; Maehr H; Rochel N
    J Steroid Biochem Mol Biol; 2017 Oct; 173():69-74. PubMed ID: 27650654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling vitamin D actions in triple negative/basal-like breast cancer.
    LaPorta E; Welsh J
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():65-73. PubMed ID: 24239860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
    Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
    Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
    Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
    Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
    Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
    Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
    Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
    Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
    Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
    Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.
    Laranjo M; Carvalho MJ; Costa T; Alves A; Oliveira RC; Casalta-Lopes J; Cordeiro P; Botas F; Abrantes AM; Paiva A; Oliveira C; Botelho MF
    Breast; 2018 Apr; 38():22-29. PubMed ID: 29182983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
    Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
    J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
    Strietz J; Stepputtis SS; Preca BT; Vannier C; Kim MM; Castro DJ; Au Q; Boerries M; Busch H; Aza-Blanc P; Heynen-Genel S; Bronsert P; Kuster B; Stickeler E; Brabletz T; Oshima RG; Maurer J
    Oncotarget; 2016 Dec; 7(50):83278-83293. PubMed ID: 27829216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.